Cargando…
Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
This editorial reflects on improvements in the cancer drug approval process of the U.S. Food and Drug Administration.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AlphaMed Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507657/ https://www.ncbi.nlm.nih.gov/pubmed/28576859 http://dx.doi.org/10.1634/theoncologist.2017-0202 |
| _version_ | 1783249769628434432 |
|---|---|
| author | Chabner, Bruce A. |
| author_facet | Chabner, Bruce A. |
| author_sort | Chabner, Bruce A. |
| collection | PubMed |
| description | This editorial reflects on improvements in the cancer drug approval process of the U.S. Food and Drug Administration. |
| format | Online Article Text |
| id | pubmed-5507657 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | AlphaMed Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55076572017-07-13 Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” Chabner, Bruce A. Oncologist Editorial This editorial reflects on improvements in the cancer drug approval process of the U.S. Food and Drug Administration. AlphaMed Press 2017-06-02 2017-07 /pmc/articles/PMC5507657/ /pubmed/28576859 http://dx.doi.org/10.1634/theoncologist.2017-0202 Text en © AlphaMed Press 2017 |
| spellingShingle | Editorial Chabner, Bruce A. Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title | Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title_full | Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title_fullStr | Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title_full_unstemmed | Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title_short | Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies” |
| title_sort | regarding “oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies” |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507657/ https://www.ncbi.nlm.nih.gov/pubmed/28576859 http://dx.doi.org/10.1634/theoncologist.2017-0202 |
| work_keys_str_mv | AT chabnerbrucea regardingoncologydrugapprovalsevaluatingendpointsandevidenceinaneraofbreakthroughtherapies |